Medical studies with striking results often prove false

October 24, 2012 by Eryn Brown, Los Angeles Times

If a medical study seems too good to be true, it probably is, according to a new analysis.

In a of nearly 230,000 trials compiled from a variety of disciplines, study results that claimed a "very large effect" rarely held up when other research teams tried to replicate them, researchers reported in Wednesday's edition of the .

"The effects largely go away; they become much smaller," said Dr. John Ioannidis, the Stanford researcher who was the report's senior author. "It's likely that most interventions that are effective have modest effects."

Ioannidis and his colleagues came to this conclusion after examining 228,220 trials grouped into more than 85,000 "topics" - collections of studies that paired a single (such as taking a non-steroidal anti- for postoperative pain) with a single outcome (such as experiencing 50 percent relief over six hours). In 16 percent of those topics, at least one study in the group claimed that the intervention made patients at least five times more likely to either benefit or suffer compared with control patients who did not receive the treatment.

In at least 90 percent of those cases, the team found, including data from subsequent trials reduced those odds.

The analysis revealed several reasons to question the significance of the very-large-effect studies, Ioannidis said.

Studies that reported striking results were more likely to be small, with fewer than 100 subjects who experienced fewer than 20 medical events. With such small sample sizes, Ioannidis said, large effects are more likely to be the result of chance.

"Trials need to be of a magnitude that can give useful information," he said.

What's more, the studies that claimed a very large effect tended to measure intermediate effects - for example, whether patients who took a reduced their levels of in their blood - rather than incidence of disease or death itself, outcomes that are more meaningful in assessing medical treatments.

The analysis did not examine individual study characteristics, such as whether the experimental methods were flawed.

The report should remind patients, physicians and policymakers not to give too much credence to small, early studies that show huge treatment effects, Ioannidis said.

One such example: the cancer drug Avastin. Clinical trials suggested the drug might double the time breast cancer patients could live with their disease without getting worse. But follow-up studies found no improvements in progression-free survival, overall survival or patients' quality of life. As a result, the U.S. Food and Drug Administration in 2011 withdrew its approval to use the drug to treat breast cancer, though it is still approved to treat several other types of cancer.

With early glowing reports, Ioannidis said, "one should be cautious and wait for a better trial."

Dr. Rita Redberg, a cardiologist at the University of California, San Francisco who was not involved in the study, said devices and drugs frequently get accelerated approval on the basis of small studies that use intermediate end points.

"Perhaps we don't need to be in such a rush to approve them," she said.

The notion that dramatic results don't hold up under closer scrutiny isn't new. Ioannidis, a well-known critic of the methods used in medical research, has written for years about the ways studies published in peer-reviewed journals fall short. (He's perhaps best known for a 2005 essay in the journal PLoS Medicine titled, "Why Most Published Research Findings Are False.")

But the scope of the JAMA analysis sets it apart from Ioannidis' earlier efforts, said Dr. Gordon Guyatt, a clinical epidemiologist at McMaster University in Hamilton, Canada, who was not involved in the work.

"They looked through a lot of stuff," he said.

Despite widespread recognition that big effects are likely to disappear upon further scrutiny, people still "get excited, and misguidedly so" when presented with home-run results, Guyatt said.

He emphasized that modest effects could benefit patients and were often "very important" on a cumulative basis.

Explore further: Association between biomarkers and disease often overstated, researcher finds

Related Stories

Association between biomarkers and disease often overstated, researcher finds

May 31, 2011
More than two dozen widely cited studies linking genes or other "biomarkers" to specific diseases vastly overstate the association, according to new research from an expert in scientific study design at the Stanford University ...

5 Questions: Ioannidis on the need to test medical 'truths'

January 6, 2012
(Medical Xpress) -- How many established standards of medical care are wrong? Disturbingly, no one knows for sure, but one study suggests that it could be almost half, according to a commentary published in the Jan. 4 issue ...

Stanford researchers suggest ways for physicians to individualize cost-effectiveness of treatments

July 12, 2011
In an era of skyrocketing health-care costs and finite financial resources, health economists are increasingly called upon to determine which medical treatments are the most cost-effective. To do so, they compare the price ...

Most large treatment effects of medical interventions come from small studies

October 23, 2012
In an examination of the characteristics of studies that yield large treatment effects from medical interventions, these studies were more likely to be smaller in size, often with limited evidence, and when additional trials ...

Recommended for you

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Lurker2358
not rated yet Oct 24, 2012
...rather than incidence of disease or death itself, outcomes that are more meaningful in assessing medical treatments.


Really? Death is pretty universal, and is likely to be so for at least the next several decades, if not quite a bit longer than that. This standard is a bit silly, since many diseases don't actually have a permanent "cure" but only treatments for symptoms or perhaps to slow down the progression.

The analysis did not examine individual study characteristics, such as whether the experimental methods were flawed.


All medical experiments are flawed, because it's impossible to control for everything that could be contaminating the results. Patient age, genetics, lifestyle, diet, exercise, employment, random accidents like unknown chemical or cosmic ray exposure or God only knows what else.

One rides a bike to work, the other rides in a car. The guy on the bike gets lung cancer from breathing unfiltered air, but you don't see a connection in the lab...
riogranderift
not rated yet Oct 25, 2012
Only confirms what we are all taught in training. I hope tax money wasn't spent doing this study. Something bothers me about those who make a living mining data generated by those doing actual research.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.